ruxolitinib
Selected indexed studies
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. (Clin Pharmacokinet, 2023) [PMID:37000342]
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (Drugs, 2024) [PMID:38625661]
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (N Engl J Med, 2012) [PMID:22375971]
_Worker-drafted node — pending editorial review._
Connections
ruxolitinib is a side effect of
Sources
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. (2023) pubmed
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (2024) pubmed
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (2012) pubmed
- Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. (2020) pubmed
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera. (2015) pubmed
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. (2023) pubmed
- Ruxolitinib. (2014) pubmed
- Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study. (2024) pubmed
- Ruxolitinib for the treatment of graft-versus-host disease. (2020) pubmed
- Myelofibrosis: Treatment Options After Ruxolitinib Failure. (2025) pubmed